SEC Form 4 · accession 0001127602-17-029287

GILEAD SCIENCES, INC. · GILD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP Comm&Acs ALA, Corp&Med Aff

Period of report

Oct 2, 2017

Accepted (ET)

Oct 4, 2017 · 7:26 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000882095

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Oct 2, 2017	M	17,250	$24.905	A	93,738	D
Common Stock^F3	Oct 2, 2017	S	2,921	$81.8406	D	90,817	D
Common Stock^F4	Oct 2, 2017	S	19,938	$82.6779	D	70,879	D
Common Stock^F5	Oct 2, 2017	S	2,141	$83.5211	D	68,738	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-qualified Stock Option (Right to Buy)^F2	$24.905	Oct 2, 2017	M	17,250	D	—	Jul 29, 2019	Common Stock	17,250	33,376	D

F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
F3Sale prices reported for the transactions reported here range from $81.28 to $82.28. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
F4Sale prices reported for the transactions reported here range from $82.31 to $83.26. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
F5Sale prices reported for the transactions reported here range from $83.315 to $83.62. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.